In Q4, Elevidys' revenue declined by about 2% year over year. Sarepta Therapeutics might have to deal with this issue for some time, and as long as it does, investors should stay away. The stock is ...

We recently published a list of Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential. In this article, ...

Sarepta Therapeutics, Inc.’s SRPT share price has surged by 6.43%, which has investors questioning if this is right time to sell.

Here are the latest rating downgrades by Seeking Alpha analysts: British American Tobacco (NYSE:BTI). Hold to sell by Michael ...

We recently published an article titled Why These 10 Firms Nosedived Today. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Uncertainty around ELEVIDYS sales impact Sarepta Therapeutics, Inc. Click here to find out why I downgraded SRPT stock to a ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 20.5% in the afternoon session after the company reported ...

Shares of Sarepta Therapeutics cratered on Wednesday after the biopharmaceutical company trimmed its full-year forecast for ...

Sarepta Therapeutics Q1 2025 revenue beat expectations, but EPS missed, and cash reserves dropped significantly. Click here ...

WEDNESDAY, May 7, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a ...

Disney surges, Uber stumbles, and AMD gains as US stocks edge higher today. Traders focus on Fed policy signals and sector ...